GSK says Indian price lock to hurt sales; Eastern Europe underpins Stada sales; 90 long enough to live, Americans say;

@FiercePharma: Tyson suspends use of Merck growth enhancer for cattle b/c some having difficulty walking. Merck says Zilmax safe. Item | Follow @FiercePharma

@CarlyHFierce: ICYMI: On Vivus' Q2 earnings and plans from new CEO Tony Zook (formerly of AstraZeneca) to increase Qsymia sales. More | Follow @CarlyHFierce

> Stada said sales of OTC drugs in Eastern Europe offset a decline in revenues in its home market of Germany, leading to a 7% lift in first half adjusted earnings. Story

> GlaxoSmithKline ($GSK) expects an expanded price control list in India to trim about 5% off its annual sales. Story

> Tyson Foods will no longer buy cattle that were fed Merck's ($MRK) Zilmax over concerns that problems that some cattle have had walking could be tied to the growth additive. Story

> Ariad Pharmaceuticals ($ARIA), based in Cambridge, MA, said the launch of its new cancer drug Iclusig added administrative costs and led to a wider quarterly loss. Story

> Indian generics maker Sun Pharmaceutical Industries saw its shares slide 5% after its Taro Pharmaceutical Industries subsidiary reported quarterly sales were off 7%. Report

Medical Device News

@FierceMedDev: Alere declares victory in proxy challenge. Article | Follow @FierceMedDev

@DamianFierce: Losses mounting, Invacare sells off another unit for $45M. Story | Follow @DamianFierce

@MichaelGFierce: Luminex axing 5% of workforce as reimbursement dries up. Article | Follow @MichaelGFierce

> CareFusion saddled with yet another Class I recall. More

> SetPoint snags $27M from GSK, Covidien. Story

> Thermo lops off 240 jobs as it preps for Life Tech merger. Article

Biotech News

@FierceBiotech: Ousted scientist fires back at GSK's high-pressure R&D strategy in China. Story | Follow @FierceBiotech

@JohnCFierce: Is the silly season on biotech IPOs over? No, Intrexon debuts with $2B market value. Item | Follow @JohnCFierce

@RyanMFierce: Biotech M&A gossip: Amgen buyout of Onyx could happen soon. More | Follow @RyanMFierce

@EmilyMFierce: NIH to open genomic data of HeLa cells to researchers. Article | Follow @EmilyMFierce

> Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk. More

> GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort. Report

> Array slashes staff as Amgen pulls the plug on diabetes drug pact. News

Vaccines News

> Flu vaccine tablet developer raises $20M. News

> PharmAthene to add antibody assets in Theraclone merger. Item

> Sanofi advances C. diff vaccine into PhIII. More

> Israel buys 500,000 polio vaccines for immunization push. Article

> GSK adding 2-D barcode to 4-in-1 flu vaccine packaging. Story

> Dana-Farber sees promise in leukemia vaccine trial. More

Pharma Manufacturing News

@EricPFierce: Pharma Tech Industries to expand facility in Missouri Story | Follow @EricPFierce

> GAO report says FDA needs clear authority over compounders. News

> Ranbaxy gets site for second Malaysian plant. Story

> When it comes to Viagra, counterfeiters just can't get enough. Article

> Endo investing $100M in Qualitest manufacturing. More

> Recall expert takes services to Europe. Item

And Finally... A new survey from the Pew Research Center found that Americans, in the face of advances in medicine, would like to live to 90, but most see no advantage in lingering much beyond that. Story

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.